Yes Kabonk, you are correct in saying that the peak in by the DSMB was to check on deaths/adverse events. Now, we wait for the interim into as many as they have at 195 or more and that is when, if they see, significant efficacy over placebo/SOC, they can then halt the trial at that point and CYDY can report that to the FDA and hopefully we get approval.

Let's just hope that they like what they see at that point of the interim readout - GLTU

HCIT